Gene
SMARCB1
SMARCB1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (36), Actionable biomarkers (3), Trial mentions (44), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SMARCB1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 8 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 5 of 8,738 | 0.06% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 8 of 11,460 | 0.07% |
| 2022 | 5 of 8,285 | 0.06% | 6 of 13,598 | 0.04% |
| 2021 | 1 of 8,692 | 0.01% | 12 of 15,045 | 0.08% |
| 2020 | 4 of 7,640 | 0.05% | 8 of 14,459 | 0.06% |
| 2019 | 1 of 7,300 | 0.01% | 13 of 12,159 | 0.11% |
| 2018 | 4 of 6,927 | 0.06% | 9 of 11,854 | 0.08% |
| 2017 | 2 of 6,558 | 0.03% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (36)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Ventana Roche | Unclassified | Clinical validation | 1 | December 01, 2021 |
| ABCAM | Reagent supplier | Clinical validationAnalytical validation | 4 | July 01, 2021 |
| Atlas Antibodies | Reagent supplier | Clinical validation | 2 | July 01, 2021 |
| BD PharMingen | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | July 01, 2021 |
| BioGenex | Reagent supplier | Clinical validation | 2 | July 01, 2021 |
Showing 5 of 36 assay-provider companies.
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SMARCB1 oncogenic mutation | Hdac Inhibitors | response-associated | malignant rhabdoid tumour | Cancer Genome Interpreter |
| SMARCB1 deletion | Ezh2 Inhibitors | response-associated | malignant rhabdoid tumour | Cancer Genome Interpreter |
| SMARCB1 oncogenic mutation | Ezh2 Inhibitors | response-associated | malignant rhabdoid tumour | Cancer Genome Interpreter |
Trial mentions (44)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04416568 | Trial eligibility (AACT) |
| NCT07438626 | Trial eligibility (AACT) |
| NCT03375307 | Trial eligibility (AACT) |
| NCT04266912 | Trial eligibility (AACT) |
| NCT05684692 | Trial eligibility (AACT) |
Showing 5 of 44 trial mentions.
Target-disease associations (454)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Andersen-Tawil syndrome | genetic, familial or congenital disease | Literature (Europe PMC) |
| Angiomatous Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 454 associations.
Vendor sourcing (169)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogeic with strong evidence (ClinVar VCV00021... | View ClinVar record SCV002011943.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000605225.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV000664943.5 |
| Ascentage Pharma Group Inc. (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 in dose escalation or 0 to 2 in dose expansion * Has a life expectancy of ... | View trial NCT05415098 |
| Ascentage Pharma Group Inc. (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | SMARCB1 | View trial NCT05415098 |
Showing 5 of 169 sourcing records.
Trial-cited literature (124)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | 35 |
| Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups. | British journal of haematology | 2025 | 2 |
| Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes. | JCO precision oncology | 2025 | 0 |
| Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson's Disease and parkinsonism. | BMC neurology | 2024 | 3 |
Showing 5 of 124 papers.
Protein variant mentions (11)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E40X | 1 | 2011 | PMID 21809989 |
| p.G11R | 1 | 2015 | PMID 25741868 |
| p.G271E | 1 | 2015 | PMID 25741868 |
| p.K363E | 1 | 2015 | PMID 25741868 |
| p.K363N | 2 | 2014 to 2015 | PMID 25741868, PMID 25326635 |
Showing 5 of 11 variants.
Literature-extracted relations (17)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors. | 2025 |
| Neoplasms | Disease | associate |
Molecularly Defined Thoracic Neoplasms. | 2024 |
| Sarcoma | Disease | inhibit |
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma. | 2024 |
| Carcinoma, Renal Cell | Disease | associate |
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. | 2022 |
| Pancreatic Neoplasms | Disease | associate |
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. | 2021 |
Showing 5 of 17 relation assertions.
Organizations publishing (231)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 13 | 2009 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 12 | 2015 to 2025 |
| Harris Health System | Hospital | 7 | 2013 to 2022 |
| CERCA Institution | Government | 6 | 2013 to 2022 |
| Harvard Medical School | Academic | 6 | 2004 to 2025 |
Showing 5 of 231 organizations.
Where SMARCB1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- integumentary system disease
- measurement
- nervous system disease
- phenotype
- urinary system disease
361 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.